Tularik Inc. (TLRK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (415)	2/2/2003 3:27:26 AM
From: Czechsinthemail	Read Replies (1) of 598

Peter, Looks like no one has responded to your request. Here's what I can offer you on T67. Tularik released information at the ASCO meeting last May. My sense was that they didn't have overwhelming results but planned to increase dosage for the pivotal trial. That sounded reasonably positive unless the side effects problems are intolerable. The big pluses are that they are going for a market without a gold standard therapy and using survival as their primary endpoint. So if they do reasonably well, T67 may be given a pass as the best in a bad situation. The downside seems to be modest market potential - at least in the U.S.-- along with the lingering uncertainties about what kind of efficacy/side effects T67 shows using the new dosing regime. Message 17924132 siliconinvestor.com Perhaps others can provide more.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next